CMX001

• CAT Number: I003575
• CAS Number: 444805-28-1
• Molecular Formula: C27H52N3O7P
• Molecular Weight: 561.70
• Purity: 98%
• Synonyms: [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid
• Target: CMV; HSV; Orthopoxvirus
• Solubility: 10 mM in DMSO
• Appearance: Solid powder
• Storage: Store at -20C
• IC50: 5.5 nM (EC50, in PDA at 7 dpi) [3]
• InChI: InChI=1S/C27H52N3O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-35-20-16-21-37-38(33,34)24-36-25(23-31)22-30-18-17-26(28)29-27(30)32/h17-18,25,31H,2-16,19-24H2,1H3,(H,33,34)(H2,28,29,32)/t25-/m0/s1
• InChIKey: WXJFKKQWPMNTIM-VWLOTQADSA-N
• SMILES: CCCCCCCCCCCCCCCCOCCCOP(=O)(CO[C@@H](CN1C=CC(=NC1=O)N)CO)O

CMX001（Cat No.:I003575）is an antiviral compound with broad-spectrum activity, primarily targeting DNA viruses such as cytomegalovirus (CMV), herpes simplex virus (HSV), and varicella-zoster virus (VZV). It is a prodrug of brincidofovir, a nucleotide analog that inhibits viral DNA polymerase. CMX001 demonstrates potent antiviral efficacy by preventing viral replication, particularly in immunocompromised patients. Its formulation offers enhanced bioavailability and prolonged half-life, making it a promising candidate for the prevention and treatment of various viral infections, including CMV-related complications in organ transplant recipients. CMX001 is currently undergoing clinical evaluation for its therapeutic potential.

Reference

1:Brincidofovir (CMX001) inhibits BK polyomavirus replication in primary human urothelial cells. Tylden GD, Hirsch HH, Rinaldo CH.Antimicrob Agents Chemother. 2015;59(6):3306-16. doi: 10.1128/AAC.00238-15. Epub 2015 Mar 23. PMID: 25801568 Free PMC Article
2:Treatment of BK virus-associated nephropathy with CMX001 after kidney transplantation in a young child. Reisman L, Habib S, McClure GB, Latiolais LS, Vanchiere JA.Pediatr Transplant. 2014 Nov;18(7):E227-31. doi: 10.1111/petr.12340. Epub 2014 Aug 30. PMID: 25174393
3:Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus. Parker S, Crump R, Foster S, Hartzler H, Hembrador E, Lanier ER, Painter G, Schriewer J, Trost LC, Buller RM.Antiviral Res. 2014 Nov;111:42-52. doi: 10.1016/j.antiviral.2014.08.003. Epub 2014 Aug 13. PMID: 25128688
4:Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses. Florescu DF, Keck MA.Expert Rev Anti Infect Ther. 2014 Oct;12(10):1171-8. doi: 10.1586/14787210.2014.948847. Epub 2014 Aug 13. PMID: 25120093
5:CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM, Brundage TM, Robertson AT, Godkin S, Momméja-Marin H, Boeckh M; CMX001-201 Clinical Study Group..N Engl J Med. 2013 Sep 26;369(13):1227-36. doi: 10.1056/NEJMoa1303688. PMID: 24066743 Free Article
6:Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. James SH, Price NB, Hartline CB, Lanier ER, Prichard MN.Antimicrob Agents Chemother. 2013 Jul;57(7):3321-5. doi: 10.1128/AAC.00062-13. Epub 2013 May 6. PMID: 23650158 Free PMC Article
7:Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. Lederman ER, Davidson W, Groff HL, Smith SK, Warkentien T, Li Y, Wilkins KA, Karem KL, Akondy RS, Ahmed R, Frace M, Shieh WJ, Zaki S, Hruby DE, Painter WP, Bergman KL, Cohen JI, Damon IK.J Infect Dis. 2012 Nov;206(9):1372-85. doi: 10.1093/infdis/jis510. Epub 2012 Aug 16. PMID: 22904336 Free PMC Article
8:First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Painter W, Robertson A, Trost LC, Godkin S, Lampert B, Painter G.Antimicrob Agents Chemother. 2012 May;56(5):2726-34. doi: 10.1128/AAC.05983-11. Epub 2012 Mar 5. PMID: 22391537 Free PMC Article
9:Treatment of Vaccinia and Cowpox Virus Infections in Mice with CMX001 and ST-246. Quenelle DC, Kern ER.Viruses. 2010 Dec;2(12):2681-95. doi: 10.3390/v2122681. Epub 2010 Dec 13. PMID: 21994637 Free PMC Article
10:Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Florescu DF, Pergam SA, Neely MN, Qiu F, Johnston C, Way S, Sande J, Lewinsohn DA, Guzman-Cottrill JA, Graham ML, Papanicolaou G, Kurtzberg J, Rigdon J, Painter W, Mommeja-Marin H, Lanier R, Anderson M, van der Horst C.Biol Blood Marrow Transplant. 2012 May;18(5):731-8. doi: 10.1016/j.bbmt.2011.09.007. Epub 2011 Sep 29. PMID: 21963623 Free PMC Article